These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
511 related items for PubMed ID: 19492955
41. Ocular penetration of grepafloxacin after intravitreal administration in albino and pigmented rabbits. Solans C, Bregante MA, Garcia MA, Perez S. Chemotherapy; 2004 Jun; 50(3):133-7. PubMed ID: 15282440 [Abstract] [Full Text] [Related]
42. Penetration and effectiveness of prophylactic fluoroquinolones in experimental methicillin-sensitive or methicillin-resistant Staphylococcus aureus anterior chamber infections. Balzli CL, Caballero AR, Tang A, Weeks AC, O'Callaghan RJ. J Cataract Refract Surg; 2010 Dec; 36(12):2160-7. PubMed ID: 21111321 [Abstract] [Full Text] [Related]
43. Comparative efficacy of besifloxacin and other fluoroquinolones in a prophylaxis model of penicillin-resistant Streptococcus pneumoniae rabbit endophthalmitis. Norcross EW, Sanders ME, Moore Q, Sanfilippo CM, Hesje CK, Shafiee A, Marquart ME. J Ocul Pharmacol Ther; 2010 Jun; 26(3):237-43. PubMed ID: 20565309 [Abstract] [Full Text] [Related]
44. Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis. Sanders ME, Moore QC, Norcross EW, Shafiee A, Marquart ME. J Ocul Pharmacol Ther; 2010 Apr; 26(2):193-8. PubMed ID: 20334537 [Abstract] [Full Text] [Related]
47. The effect of cataract surgery on ocular levels of topical moxifloxacin. Mather R, Stewart JM, Prabriputaloong T, Wong J, McLeod SD. Am J Ophthalmol; 2004 Oct; 138(4):554-9. PubMed ID: 15488780 [Abstract] [Full Text] [Related]
48. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Hariprasad SM, Blinder KJ, Shah GK, Apte RS, Rosenblatt B, Holekamp NM, Thomas MA, Mieler WF, Chi J, Prince RA. Arch Ophthalmol; 2005 Jan; 123(1):39-44. PubMed ID: 15642810 [Abstract] [Full Text] [Related]
49. Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients. Lindstrom R, Lane S, Cottingham A, Smith S, Sall K, Silverstein S, Shettle L, Walters T, Faulkner R, Cockrum P, Teuscher N. J Ocul Pharmacol Ther; 2010 Dec; 26(6):591-5. PubMed ID: 20925517 [Abstract] [Full Text] [Related]
50. Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers. Walters T, Rinehart M, Krebs W, Holdbrook M. Cornea; 2010 Mar; 29(3):263-8. PubMed ID: 20098307 [Abstract] [Full Text] [Related]
51. Measurement of AQCmax of five different ophthalmic solutions and discussion of its new application. Fukuda M, Sasaki H. J Ocul Pharmacol Ther; 2009 Aug; 25(4):351-6. PubMed ID: 19650709 [Abstract] [Full Text] [Related]
52. Ocular pharmacokinetics of topically-applied ketoconazole solution containing hydroxypropyl beta-cyclodextrin to rabbits. Zhang J, Wang L, Gao C, Zhang L, Xia H. J Ocul Pharmacol Ther; 2008 Oct; 24(5):501-6. PubMed ID: 18803444 [Abstract] [Full Text] [Related]
53. Metabolism and ocular tissue distribution of an antiglaucoma prostanoid, tafluprost, after ocular instillation to monkeys. Fukano Y, Kawazu K, Akaishi T, Bezwada P, Pellinen P. J Ocul Pharmacol Ther; 2011 Jun; 27(3):251-9. PubMed ID: 21491995 [Abstract] [Full Text] [Related]
54. Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey. Savinainen A, Prusakiewicz JJ, Oswald J, Spencer E, Lou Z, Cohen ML, Rashidzadeh H, Josiah S. Exp Eye Res; 2019 Dec; 189():107836. PubMed ID: 31626797 [Abstract] [Full Text] [Related]
55. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials. Comstock TL, Paterno MR, Usner DW, Pichichero ME. Paediatr Drugs; 2010 Apr 01; 12(2):105-12. PubMed ID: 20218747 [Abstract] [Full Text] [Related]
56. Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates. Sanfilippo CM, Allaire CM, DeCory HH. Drugs R D; 2017 Mar 01; 17(1):167-175. PubMed ID: 28078599 [Abstract] [Full Text] [Related]
57. Treatment of experimental bacterial keratitis with topical trovafloxacin. Barequet IS, Denton P, Osterhout GJ, Tuli S, O'Brien TP. Arch Ophthalmol; 2004 Jan 01; 122(1):65-9. PubMed ID: 14718297 [Abstract] [Full Text] [Related]
58. Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. Stewart WC, Crean CS, Zink RC, Brubaker K, Haque RM, Hwang DG. Am J Ophthalmol; 2010 Nov 01; 150(5):744-751.e2. PubMed ID: 20813346 [Abstract] [Full Text] [Related]
59. Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae. Haas W, Pillar CM, Hesje CK, Sanfilippo CM, Morris TW. J Antimicrob Chemother; 2010 Jul 01; 65(7):1441-7. PubMed ID: 20435780 [Abstract] [Full Text] [Related]
60. Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing. Levine JM, Noecker RJ, Lane LC, Herrygers L, Nix D, Snyder RW. J Cataract Refract Surg; 2004 Oct 01; 30(10):2177-82. PubMed ID: 15474833 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]